Zhou C - Search Results

1

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).

Xu CR, Chen Q, Zhou C, Wu L, Li W, Zhang H, Li Y, Xu F, Xiong J, Wang Q, Zhang H, Jiang Y, Yin H, Wu Q, Dai Q, Hu J, Chen J, Zhang J, Wu G, Yin J, Zhao J, Liu B, Shan J, Sheng L, Chen Q, Han Z, Shi H, Liu Y, Chen J, Wu YL. Xu CR, et al. Among authors: zhou c. Transl Lung Cancer Res. 2023 Jan 31;12(1):127-140. doi: 10.21037/tlcr-22-852. Epub 2023 Jan 16. Transl Lung Cancer Res. 2023. PMID: 36762057 Free PMC article.

2

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.

He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J. He C, et al. Among authors: zhou c. Int J Cancer. 2009 Nov 15;125(10):2393-9. doi: 10.1002/ijc.24653. Int J Cancer. 2009. PMID: 19530244

3

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients.

Liu Z, Wu L, Cao J, Yang Z, Zhou C, Cao L, Wu H, Shen H, Jin M, Zhang Y, Mao X, Xiang J, Ma K, Li B, Zhang T, Hu Y. Liu Z, et al. Among authors: zhou c. Onco Targets Ther. 2018 Oct 23;11:7323-7331. doi: 10.2147/OTT.S173391. eCollection 2018. Onco Targets Ther. 2018. PMID: 30425522 Free PMC article.

4

The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients.

Li M, Zhou CZ, Yang JJ, Lu S, Zheng D, Hu J, Zeng H, Lu Y, Lu KH, Li SA, Mao XR, Han-Zhang H, Lizaso A, Ye JY, Hu CP. Li M, et al. Cancer Biol Ther. 2019;20(8):1097-1104. doi: 10.1080/15384047.2019.1595280. Epub 2019 Apr 16. Cancer Biol Ther. 2019. PMID: 30990107 Free PMC article.

5

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Song P, Cui X, Bai L, Zhou X, Zhu X, Zhang J, Jin F, Zhao J, Zhou C, Zhou Y, Zhang X, Wang K, Wang Q, Yu Y, Zhang X, Bai C, Zhang L. Song P, et al. Among authors: zhou x, zhou y, zhou c. Thorac Cancer. 2019 May;10(5):1303-1309. doi: 10.1111/1759-7714.13078. Epub 2019 Apr 23. Thorac Cancer. 2019. PMID: 31016875 Free PMC article.

6

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

Yang Y, Zhou J, Zhou J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wu N, Song W, Liu X, Zhao S, Ding L, Mao L, Selvaggi G, Yuan X, Fu Y, Wang T, Xiao S, Zhang L. Yang Y, et al. Among authors: zhou j, zhou c. Lancet Respir Med. 2020 Jan;8(1):45-53. doi: 10.1016/S2213-2600(19)30252-8. Epub 2019 Oct 15. Lancet Respir Med. 2020. PMID: 31628085 Clinical Trial.

7

Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.

Fan Y, Chen J, Zhou C, Wang H, Shu Y, Zhang J, Hua H, Huang DC, Zhou C. Fan Y, et al. Among authors: zhou c. Lung Cancer. 2020 Sep;147:209-213. doi: 10.1016/j.lungcan.2020.07.017. Epub 2020 Jul 16. Lung Cancer. 2020. PMID: 32738416 Free article. Clinical Trial.

8

A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.

Jin S, Zhou C, Hou X, Fan Z, Zhao J, Ai X, Chu Y, Chen R, Guo R, Chen L. Jin S, et al. Among authors: zhou c. Transl Lung Cancer Res. 2020 Aug;9(4):1507-1515. doi: 10.21037/tlcr-20-882. Transl Lung Cancer Res. 2020. PMID: 32953522 Free PMC article.

9

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment.

Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, Ouyang M, Zhou CZ. Xie XH, et al. Cancer Manag Res. 2020 Dec 10;12:12709-12714. doi: 10.2147/CMAR.S278068. eCollection 2020. Cancer Manag Res. 2020. PMID: 33328765 Free PMC article.

10

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.

Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S, Liu C, Liu D, Liu W, Liu Y, Ma H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Zhong R, Li F, Rosell R, Provencio M, Massarelli E, Antonoff MB, Hida T, de Perrot M, Lin SH, Di Maio M, Rossi A, De Ruysscher D, Ramirez RA, Dempke WCM, Camidge DR, Guibert N, Califano R, Wang Q, Ren S, Zhou C, He J. Liang W, et al. Among authors: zhou c. Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63. Transl Lung Cancer Res. 2020. PMID: 33489828 Free PMC article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20,835 results

Search Page

Filters